Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Awada

Showing results (171-180 of 210) with videos related to

Pageof 21
Sort By:
Investigational New Drugs|January 25, 2013
Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumorsF E Stuurman, E E Voest, A Awada, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 6, 2003
Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapyM J Piccart, A Floquet, G Scarfone, et al.
British Journal of Cancer|May 5, 2005
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumoursA Awada, A Hendlisz, T Gil, et al.
Brain, Behavior, and Immunity|June 8, 2020
Acarbose protects from central and peripheral metabolic imbalance induced by benzene exposureL K Debarba, A Mulka, J B M Lima, et al.
British Journal of Cancer|April 3, 1999
Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus scheduleA Awada, C J Punt, M J Piccart, et al.
Anti-Cancer Drugs|August 1, 1994
Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusionH A Burris, A Awada, J G Kuhn, et al.
ESMO Open|December 20, 2021
Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global surveyT Cufer, M Kosty, P Osterlund, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 1997
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast CancerM J Piccart, J Klijn, R Paridaens, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 7, 2008
The use of low-energy laser (LEL) for the prevention of chemotherapy- and/or radiotherapy-induced oral mucositis in cancer patients: results from two prospective studiesM T Genot-Klastersky, J Klastersky, F Awada, et al.
Cancer Chemotherapy and Pharmacology|September 6, 2000
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)N Pavlidis, S Aamdal, A Awada, et al.
Pageof 21

Showing results (171-180 of 210) with videos related to

Sort By:
Pageof 21
Investigational New Drugs|January 25, 2013
Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumorsF E Stuurman, E E Voest, A Awada, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 6, 2003
Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapyM J Piccart, A Floquet, G Scarfone, et al.
British Journal of Cancer|May 5, 2005
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumoursA Awada, A Hendlisz, T Gil, et al.
Brain, Behavior, and Immunity|June 8, 2020
Acarbose protects from central and peripheral metabolic imbalance induced by benzene exposureL K Debarba, A Mulka, J B M Lima, et al.
British Journal of Cancer|April 3, 1999
Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus scheduleA Awada, C J Punt, M J Piccart, et al.
Anti-Cancer Drugs|August 1, 1994
Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusionH A Burris, A Awada, J G Kuhn, et al.
ESMO Open|December 20, 2021
Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global surveyT Cufer, M Kosty, P Osterlund, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 1997
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast CancerM J Piccart, J Klijn, R Paridaens, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 7, 2008
The use of low-energy laser (LEL) for the prevention of chemotherapy- and/or radiotherapy-induced oral mucositis in cancer patients: results from two prospective studiesM T Genot-Klastersky, J Klastersky, F Awada, et al.
Cancer Chemotherapy and Pharmacology|September 6, 2000
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)N Pavlidis, S Aamdal, A Awada, et al.
Pageof 21